Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Fusion Pharmaceuticals Inc. (FUSN)

2.75   0.02 (0.73%) 06-26 19:51
Open: 3.05 Pre. Close: 2.73
High: 3.05 Low: 2.64
Volume: 59,163 Market Cap: 119(M)
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.05 - 3.07 3.07 - 3.08
Low: 2.61 - 2.62 2.62 - 2.64
Close: 2.73 - 2.75 2.75 - 2.77

Technical analysis

as of: 2022-06-24 4:40:08 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.11     One year: 4.75
Support: Support1: 2.64    Support2: 2.19
Resistance: Resistance1: 3.52    Resistance2: 4.07
Pivot: 3.4
Moving Average: MA(5): 3.04     MA(20): 3.45
MA(100): 5.86     MA(250): 6.66
MACD: MACD(12,26): -0.4     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 5.1     %D(3): 5.3
RSI: RSI(14): 14.1
52-week: High: 9.5  Low: 2.64
Average Vol(K): 3-Month: 18 (K)  10-Days: 27 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ FUSN ] has closed below the lower bollinger band by 1.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ FUSN ] is to continue within current trading range. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sun, 26 Jun 2022
Mobile E-Commerce Software Market Booming Worldwide With Leading Key Players -Shopgate, Shopify Mobile App Builder, Moltin, Branding Brand, Elastic Path, Knowband, AmazingCart, Apptuse Go, Contus, Dynamicweb, Elite mCommerce, exporthub, Fus - Indian Defence News

Thu, 23 Jun 2022
Fusion Pharmaceuticals Inc (FUSN) Stock Falls -15.43% This Week; Should You Buy? - InvestorsObserver

Thu, 23 Jun 2022
Health Care Sector Update for 06/23/2022: FSTX, FUSN, AMYT, XLV, IBB - Nasdaq

Thu, 23 Jun 2022
Fusion Pharmaceuticals Inc. (FUSN) Announces FDA Clearance of IND for FPI-2059 - StreetInsider.com

Tue, 21 Jun 2022
FUSION PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders (form 8-K) - Marketscreener.com

Fri, 10 Jun 2022
Fusion Pharmaceuticals (FUSN) Stock Price: Why It Increased Over 4% Today - Pulse 2.0

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 43 (M)
% Held by Insiders 2.318e+007 (%)
% Held by Institutions 8.4 (%)
Shares Short 73 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -8.413e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -4
Return on Assets (ttm) 190.6
Return on Equity (ttm) -19.9
Qtrly Rev. Growth 2.02e+006
Gross Profit (p.s.) 0
Sales Per Share 0.01
EBITDA (p.s.) -1.76
Qtrly Earnings Growth -2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -70 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 140
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 80780
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.